Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab

Abstract
Two patients with chronic motor neuropathy, high antiganglioside antibody (AGA) titers, and a declining response to IV immunoglobulins were treated with rituximab at a standard dose. The drug was well tolerated and effectively eliminated peripheral B cells (CD20+), but AGA titers continued significantly high. No clinical improvement was detected during the 1-year follow-up.

This publication has 10 references indexed in Scilit: